Overview
Join our upcoming webinar to explore the latest expert consensus on ST-elevation myocardial infarction (STEMI). Learn about best practices for cardiac catheterization laboratory readiness, arterial access, diagnostic angiography, and thrombus management. Discover strategies to improve outcomes and reduce mortality for STEMI patients.
"SCAI Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary PCI" will be released on October 7, 2024.
Learning Objectives
- To discuss the strengths and limitations of various diagnostic and therapeutic interventions to assess and treat a patient with STEMI in the Cath Lab
- To review the different options to manage large thrombus burden during STEMI, and to manage no-reflow
- To review the management of STEMI across the spectrum of various anatomical and clinical circumstances
Agenda
- Introduction—Dr Yader Sandoval
- Key Points and Algorithm—Dr. Jacqueline Tamis-Holland
- Case of STEMI with Large Thrombus Burden—Dr. Celina Yong
- Case of STEMI with Refractory No-Reflow—Dr. J. Dawn Abbott
- Case of STEMI in a Large Bifurcation Vessel —Dr. Mauricio Cohen
- Takeaways
Faculty
Moderator
Yader Sandoval, MD, FSCAI
Moderator
Jacqueline Tamis-Holland, MD, FSCAI
Panelist
J. Dawn Abbott, MD, FSCAI
Panelist
Timothy D. Henry, MD, MSCAI
Registration Information
Cost: Free
Please contact education@scai.org if you have any questions or issues registering.
Disclosures
Individuals in control of content reported the following relevant financial relationships with ineligible companies during the content development process for this activity. All relevant financial relationships were mitigated before the start of the activity.
Planner
Jacqueline Tamis-Holland: No financial relationships with ineligible companies
Faculty
J. Dawn Abbott: Consulting: Abbott; PI: Boston Scientific; Shockwave; Philips
Nitin Barman: Speaker: Boston Scientific; Cardiovascular Systems Inc.
Anna Bortnick: Grant: Zoll; Honoraria: Getinge, Zoll; PI: CSL-Behring, Amgen
Mauricio Cohen: Consulting: Abbott; PI: Abbott, Boston Scientific
Tim Henry: No financial relationships with ineligible companies
Yader Sandoval: Advisory Board: Abbott; Philips; Zoll
Celina Yong: No financial relationships with ineligible companies
Reviewer
Nkechi Ijioma: No financial relationships with ineligible companies.
Staff
Alan Nguyen, Chelsea Armah, Scott Firestone: No financial relationships with ineligible companies.
Accredited Continuing Education Information
Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
SCAI designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful Completion
Watch the content and complete the evaluation to obtain credit.
SCAI's Independent Content
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.
Planning Process
SCAI activities are developed by the Publications Committee prior to and independent of commercial support. Members of the Publications Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.
Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant financial relationships and mitigates them before the activity begins.
Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company.
SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education.
SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.
Events Schedule
Learning opportunities from SCAI for the interventional cardiology team.